Based on these studies, the development of therapeutic drugs targeting RIPK1 is a new strategy to block cell death in the process of ischemic cardio-cerebrovascular diseases, inflammation, neurodegenerative diseases, and so on (Manguso et al., 2017). Here, RIPK1 is linked to neurodegenerative disease.